Dec 1, 2025 ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
Nov 12, 2025 ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
Nov 3, 2025 ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Oct 22, 2025 ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group
Sep 3, 2025 ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
Aug 13, 2025 ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
Jul 29, 2025 ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference